Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹792 Cr
up ₹15.2 Cr vs Dec 2013
- Stocks held
- 21
- up 2 vs Dec 2013
- Top 10 weight
- 78.2%
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In January 2014 it disclosed 21 stocks worth ₹792 Cr, up ₹15.2 Cr from Dec 2013. Its largest positions were Divi's Laboratories Limited (11.0%), Sanofi India Limited (9.9%), Cipla Limited (9.9%); the ten largest together made up 78.2% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 89.4% of its equity. Cash and debt stood at 0.8%. Compared with Dec 2013 the fund entered 2 new stocks and exited 0.
Against 227 other Sectoral / Thematic funds
Concentration
98%
Top-10 weight is higher than 98% of peers
Breadth
4%
Holds more stocks than 4% of peers
Cash
11%
Holds more cash than 11% of peers
Holdings in January 2014
Download CSVEvery line the fund disclosed, with the change against Dec 2013. Click a column to sort; click a company to see every fund that owns it.
| Divi's Laboratories Limited | 11.05% | up 0.59 pts | ₹87.5 Cr | up ₹6.3 Cr | Added |
| Sanofi India Limited | 9.89% | up 0.41 pts | ₹78.3 Cr | up ₹4.7 Cr | Added |
| Cipla Limited | 9.85% | up 0.56 pts | ₹78 Cr | up ₹5.9 Cr | Added |
| Abbott India Limited | 8.52% | down 0.38 pts | ₹67.4 Cr | down ₹1.7 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 8.41% | up 0.08 pts | ₹66.6 Cr | up ₹1.9 Cr | Added |
| Sun Pharmaceutical Industries Limited | 7.25% | up 0.13 pts | ₹57.4 Cr | up ₹2.1 Cr | Added |
| Biocon Limited | 6.61% | down 1.73 pts | ₹52.4 Cr | down ₹12.4 Cr | Trimmed |
| Lupin Limited | 6.13% | down 0.31 pts | ₹48.5 Cr | down ₹1.4 Cr | Trimmed |
| Zydus Lifesciences Limited | 6.01% | up 2.88 pts | ₹47.6 Cr | up ₹23.3 Cr | Added |
| GlaxoSmithKline Pharmaceuticals Limited | 4.52% | down 0.50 pts | ₹35.8 Cr | down ₹3.2 Cr | Trimmed |
| IPCA Laboratories Limited | 3.95% | up 0.43 pts | ₹31.2 Cr | up ₹3.9 Cr | Added |
| Indoco Remedies Limited | 3.79% | down 2.26 pts | ₹30 Cr | down ₹17 Cr | Trimmed |
| Zydus Wellness Limited | 3.08% | down 0.26 pts | ₹24.4 Cr | down ₹1.5 Cr | Trimmed |
| Sun Pharma Advanced Research Company Limited | 2.66% | down 0.04 pts | ₹21 Cr | up ₹12 L | Added |
| Procter & Gamble Health Limited | 2.52% | up 1.82 pts | ₹19.9 Cr | up ₹14.5 Cr | Added |
| Apollo Hospitals Enterprise Limited | 1.78% | down 0.13 pts | ₹14.1 Cr | down ₹72 L | Trimmed |
| Glenmark Pharmaceuticals Limited | 1.06% | up 1.06 pts | ₹8.4 Cr | up ₹8.4 Cr | New |
| Cash, TREPS & receivables | 0.79% | down 0.60 pts | ₹6.2 Cr | down ₹4.6 Cr | Trimmed |
| Fulford India Ltd | 0.63% | down 0.27 pts | ₹5 Cr | down ₹2 Cr | Trimmed |
| Ranbaxy Laboratories Ltd | 0.61% | down 1.72 pts | ₹4.9 Cr | down ₹13.3 Cr | Trimmed |
| Unichem Laboratories Limited | 0.59% | down 0.04 pts | ₹4.6 Cr | down ₹21 L | Trimmed |
| FDC Limited | 0.29% | up 0.29 pts | ₹2.3 Cr | up ₹2.3 Cr | New |
| Dr. Reddy'S Laboratories Ltd Debt | 0.02% | down <0.01 pts | ₹16 L | up ₹0 L | Held |
What changed, Dec 2013 to Jan 2014
New New positions (2)
- Glenmark Pharmaceuticals Limited1.1% · ₹8.4 Cr
- FDC Limited0.3% · ₹2.3 Cr
Exited Exited (0)
None.
Added Biggest additions
- Zydus Lifesciences Limitedup ₹23.3 Cr (+2.88% pts)
- Procter & Gamble Health Limitedup ₹14.5 Cr (+1.82% pts)
- Divi's Laboratories Limitedup ₹6.3 Cr (+0.59% pts)
- Cipla Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Dec 2013, the weight rose most in Pharmaceuticals & Biotechnology (+4.8 pts), and fell most in Pharmaceuticals (−4.1 pts) and Miscellaneous (−0.3 pts).
- Pharmaceuticals & Biotechnology84.6% → 89.4%+4.8 pts
- Pharmaceuticals9.1% → 5.0%−4.1 pts
- Miscellaneous0.9% → 0.6%−0.3 pts
- Food Products3.4% → 3.1%−0.3 pts
- Healthcare Services1.9% → 1.8%−0.1 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jan 2013 | Jul 2013 | Oct 2013 | Dec 2013 | Jan 2014 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 77.9% | 82.3% | 84.9% | 84.6% | 89.4% |
| Pharmaceuticals | 16.5% | 11.9% | 8.6% | 9.1% | 5.0% |
| Food Products | 4.2% | 4.2% | 3.9% | 3.4% | 3.1% |
| Healthcare Services | 0.1% | 0.8% | 1.7% | 1.9% | 1.8% |
| Miscellaneous | 1.4% | 0.8% | 1.0% | 0.9% | 0.6% |
Allocation in Jan 2014change vs Dec 2013
- Pharmaceuticals & Biotechnology (15)89.4%▲ 4.8 pts
- Pharmaceuticals (3)5.0%▼ 4.1 pts
- Food Products (1)3.1%▼ 0.3 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Cash & debt, Jan 2014
0.8%
▼ 0.6 pts vs Dec 2013
- Cash alone
- 0.8%
- cash and net receivables
- A year earlier
- 0.6%
- Jan 2013 · now ▲ 0.2 pts
- Last 12 months
- 0.3% – 2.4%
- lowest to highest · record 2.4% in May 2013
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.